You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
12.09.14
Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis
11.20.14
Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan
11.05.14
Ironwood Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
11.04.14
Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation
11.04.14
Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update
10.20.14
Ironwood Presents IW-9179 Phase IIa Data at American College of Gastroenterology 2014 Annual Scientific Meeting
10.16.14
Ironwood Pharmaceuticals Announces Initiation of Phase II Trial of Linaclotide in Adult Patients with Opioid-Induced Constipation
10.14.14
Ironwood Pharmaceuticals to Host Third Quarter 2014 Investor Update Call
10.09.14
Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting
09.03.14
Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
09.02.14
Ironwood Appoints Two New Senior Executives to Support Continued Growth as a Leader in Gastroenterology
08.04.14
Ironwood Pharmaceuticals Provides Second Quarter 2014 Investor Update
07.07.14
Ironwood Pharmaceuticals to Host Second Quarter 2014 Investor Update Call
06.05.14
Ironwood Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
06.04.14
Ironwood Pharmaceuticals Appoints Douglas Williams, Ph.D., to Board of Directors
05.07.14
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2014 Healthcare Conference
05.01.14
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2014
04.29.14
Ironwood Pharmaceuticals Provides First Quarter 2014 Investor Update
04.10.14
Ironwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS®
04.08.14
Ironwood Pharmaceuticals to Host First Quarter 2014 Investor Update Call
03.18.14
Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease
02.24.14
Ironwood Pharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference
02.13.14
Ironwood Pharmaceuticals Announces Exercise of Underwriters' Option in Public Offering of Common Stock
02.12.14
Ironwood Pharmaceuticals Appoints Julie McHugh to Board of Directors
02.11.14
Ironwood Pharmaceuticals Prices Public Offering of Common Stock
02.10.14
Ironwood Receives Notice of Allowance for Methods of Use Formulation Patent Expected to Extend LINZESS® Patent Protection Through 2031
02.10.14
Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock
02.07.14
Ironwood Pharmaceuticals to Present at Leerink Global Healthcare Conference
01.21.14
Ironwood Pharmaceuticals Provides Fourth Quarter 2013 Investor Update
01.08.14
Ironwood Pharmaceuticals Announces Alignment of Workforce with Priority Growth Platforms
01.07.14
Ironwood Pharmaceuticals to Host Fourth Quarter 2013 Investor Update Call
01.06.14
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Media contact
Meredith Kaya
617.374.5082
mkaya@ironwoodpharma.com

Latest Tweets